<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d511">
    <sentence id="DDI-DrugBank.d511.s0" text="A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.">
        <entity charOffset="31-38" id="DDI-DrugBank.d511.s0.e0" text="FOSCAVIR" type="brand"/>
        <entity charOffset="56-66" id="DDI-DrugBank.d511.s0.e1" text="pentamidine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d511.s0.e0" e2="DDI-DrugBank.d511.s0.e1" id="DDI-DrugBank.d511.s0.p0" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s1" text="Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;">
        <entity charOffset="66-73" id="DDI-DrugBank.d511.s1.e0" text="FOSCAVIR" type="brand"/>
        <entity charOffset="91-101" id="DDI-DrugBank.d511.s1.e1" text="pentamidine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d511.s1.e0" e2="DDI-DrugBank.d511.s1.e1" id="DDI-DrugBank.d511.s1.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s2" text="one patient died with severe hypocalcemia."/>
    <sentence id="DDI-DrugBank.d511.s3" text="Toxicity associated with concomitant use of aerosolized pentamidine has not been reported.">
        <entity charOffset="56-66" id="DDI-DrugBank.d511.s3.e0" text="pentamidine" type="drug"/>
    <negationtags>Toxicity associated with concomitant use of aerosolized pentamidine has &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; been reported. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d511.s4" text="Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.">
        <entity charOffset="11-19" id="DDI-DrugBank.d511.s4.e0" text="foscarnet" type="drug"/>
        <entity charOffset="69-76" id="DDI-DrugBank.d511.s4.e1" text="FOSCAVIR" type="brand"/>
        <entity charOffset="154-168" id="DDI-DrugBank.d511.s4.e2" text="aminoglycosides" type="group"/>
        <entity charOffset="171-184" id="DDI-DrugBank.d511.s4.e3" text="amphotericin B" type="drug"/>
        <entity charOffset="202-212" id="DDI-DrugBank.d511.s4.e4" text="pentamidine" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e0" e2="DDI-DrugBank.d511.s4.e1" id="DDI-DrugBank.d511.s4.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e0" e2="DDI-DrugBank.d511.s4.e2" id="DDI-DrugBank.d511.s4.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e0" e2="DDI-DrugBank.d511.s4.e3" id="DDI-DrugBank.d511.s4.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e0" e2="DDI-DrugBank.d511.s4.e4" id="DDI-DrugBank.d511.s4.p3"/>
        <pair ddi="true" e1="DDI-DrugBank.d511.s4.e1" e2="DDI-DrugBank.d511.s4.e2" id="DDI-DrugBank.d511.s4.p4" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d511.s4.e1" e2="DDI-DrugBank.d511.s4.e3" id="DDI-DrugBank.d511.s4.p5" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d511.s4.e1" e2="DDI-DrugBank.d511.s4.e4" id="DDI-DrugBank.d511.s4.p6" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e2" e2="DDI-DrugBank.d511.s4.e3" id="DDI-DrugBank.d511.s4.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e2" e2="DDI-DrugBank.d511.s4.e4" id="DDI-DrugBank.d511.s4.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s4.e3" e2="DDI-DrugBank.d511.s4.e4" id="DDI-DrugBank.d511.s4.p9"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s5" text="Since FOSCAVIR decreases serum concentrations of ionized calcium, concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution.">
        <entity charOffset="6-13" id="DDI-DrugBank.d511.s5.e0" text="FOSCAVIR" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d511.s6" text="Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.">
        <entity charOffset="0-10" id="DDI-DrugBank.d511.s6.e0" text="Ganciclovir" type="drug"/>
        <entity charOffset="37-45" id="DDI-DrugBank.d511.s6.e1" text="foscarnet" type="drug"/>
        <entity charOffset="51-61" id="DDI-DrugBank.d511.s6.e2" text="ganciclovir" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s6.e0" e2="DDI-DrugBank.d511.s6.e1" id="DDI-DrugBank.d511.s6.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s6.e0" e2="DDI-DrugBank.d511.s6.e2" id="DDI-DrugBank.d511.s6.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d511.s6.e1" e2="DDI-DrugBank.d511.s6.e2" id="DDI-DrugBank.d511.s6.p2"/>
    <negationtags>Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease. &lt;/scope&gt;</negationtags></sentence>
</document>